SB3 (Ontruzant®): A Trastuzumab Biosimilar

SB3 (Ontruzant®): A Trastuzumab Biosimilar SB3 (Ontruzant®) is the first biosimilar of the reference anti-HER2 antibody trastuzumab to be approved in the EU. It is approved for use in all indications for which reference trastuzumab is approved, namely HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer. SB3 has similar physicochemical and pharmacodynamic properties to those of reference trastuzumab, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers and women with HER2-positive early or locally advanced breast cancer. SB3 demonstrated clinical efficacy considered equivalent to that of reference trastuzumab in women with HER2-positive early or locally advanced breast cancer. The tolerability, immunogenicity and safety profiles of SB3 were similar to those of reference trastuzumab. The role of reference trastuzumab in the management of HER2-positive cancers is well established and SB3 provides an effective biosimilar alternative for patients requiring trastuzumab therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

SB3 (Ontruzant®): A Trastuzumab Biosimilar

BioDrugs , Volume 32 (3) – May 23, 2018

Loading next page...
 
/lp/springer_journal/sb3-ontruzant-a-trastuzumab-biosimilar-AJwY9dt0nD
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-018-0282-5
Publisher site
See Article on Publisher Site

Abstract

SB3 (Ontruzant®) is the first biosimilar of the reference anti-HER2 antibody trastuzumab to be approved in the EU. It is approved for use in all indications for which reference trastuzumab is approved, namely HER2-positive early breast cancer, metastatic breast cancer and metastatic gastric cancer. SB3 has similar physicochemical and pharmacodynamic properties to those of reference trastuzumab, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers and women with HER2-positive early or locally advanced breast cancer. SB3 demonstrated clinical efficacy considered equivalent to that of reference trastuzumab in women with HER2-positive early or locally advanced breast cancer. The tolerability, immunogenicity and safety profiles of SB3 were similar to those of reference trastuzumab. The role of reference trastuzumab in the management of HER2-positive cancers is well established and SB3 provides an effective biosimilar alternative for patients requiring trastuzumab therapy.

Journal

BioDrugsSpringer Journals

Published: May 23, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off